Amendment To License Agreement Sample Contracts

Cue Biopharma, Inc. – First Amendment to License Agreement (June 20th, 2018)

This First Amendment to License Agreement (this First Amendment), is made as of the 18th day of June, 2018, by and between Cue Biopharma, Inc., a Delaware corporation having a place of business located at 675 W. Kendall Street, Cambridge, Massachusetts (Licensee) and MIL 21E, LLC, a Delaware limited liability company having a place of business located at 675 West Kendall Street, Cambridge, MA 02142 (Licensor).

Immudyne Inc – First Amendment to License Agreement (June 8th, 2018)

This First Amendment (the "Amendment") to the License Agreement dated November 26, 2017 (the "License Agreement"), is made and entered into effective as of May 20, 2018 (the "Effective Date"), by and between Immudyne PR, a Puerto Rico domiciled limited liability company ("Immudyne PR or the "Licensee"), One Down, a limited liability company with a place of business at 550 Military Trail, Jupiter, FL 33458 ("One Down" or the "Licensor") and Immudyne, a Delaware domiciled corporation with a place of business at 1460 Broadway, New York NY 10036 ("Immudyne"). Capitalized terms used but not otherwise defined herein shall have the same meanings as set forth in the Services Agreement attached as Appendix A to this First Amendment.

Therapix Biosciences Ltd. – Second Amendment to License Agreement (April 30th, 2018)

THIS SECOND AMENDMENT TO LICENSE AGREEMENT (the "Second Amendment") is made as of September 17, 2017 by and between Dekel Pharmaceuticals Ltd. (the "Licensor" or "Dekel"), and Therapix Biosciences Ltd., (the "Licensee" or "Therapix"). Licensee, on the one hand, and Licensor, on the other, may each individually be referred to in this Amendment as a "Party" and collectively referred to in this Amendment as the "Parties".

First Amendment to License Agreement (April 11th, 2018)

This First Amendment to License Agreement (First Amendment), is entered on January 5, 2017, by and among RAW ENERGY MATERIALS, CORP., a Florida corporation (Licensor or Raw Energy) and ROCKSTAR ACQUISITIONS, LLC, a Florida limited liability company, (Licensee or Rockstar Acquisitions). [Each is a Party and together are the Parties. All initially capitalized terms used in this First Amendment shall have the same meanings ascribed to them in the License Agreement.]

Audentes Therapeutics, Inc. – FIRST AMENDMENT TO License Agreement (March 9th, 2018)

This FIRST AMENDMENT TO LICENSE AGREEMENT ("First Amendment") is entered into as of November 3, 2017 ("First Amendment Effective Date") by and between REGENXBIO Inc., a corporation organized under the laws of the State of Delaware, with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 ("Licensor"), and Audentes Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 600 California Street, 17th Floor, San Francisco, California, 94108 ("Licensee"). Licensor and Licensee are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Fourth Amendment to License Agreement (March 6th, 2018)

This Fourth Amendment to License Agreement (this "Fourth Amendment") is entered into as of this 5th day of December, 2017 (the "Fourth Amendment Effective Date"), by and between Tetraphase Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 480 Arsenal Street, Suite 110, Watertown, MA 02472 ("Licensee") and President and Fellows of Harvard College, Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, MA 02138 ("Harvard").

REGENXBIO Inc. – First Amendment to License Agreement (March 6th, 2018)

This First Amendment to License Agreement (the "First Amendment") is made as of January 8, 2018 (the "First Amendment Effective Date") by and between REGENXBIO Inc. (formerly known as ReGenX Biosciences, LLC), a corporation organized under the laws of the State of Delaware, with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 ("Licensor"), and AveXis, Inc., a corporation organized under the laws of the State of Delaware, with offices at 2275 Half Day Road, Suite 200, Bannockburn, IL 60015 ("Licensee"). Licensor and Licensee are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Homology Medicines, Inc. – Confidential Treatment Requested by Homology Medicines, Inc. FIRST AMENDMENT TO LICENSE AGREEMENT (March 2nd, 2018)

This amendment to the License Agreement (the First License Amendment), effective on the date last signed below, (Amendment Effective Date) is by and between Homology Medicines, Inc., a Delaware corporation having a place of business at 45 Wiggins Avenue, Bedford, MA 01730 (HMI) and California Institute of Technology, a not-for-profit corporation duly organized and existing under the laws of the State of California with an address at 1200 East California Boulevard, MC 6-32, Pasadena, California 91125 (Caltech; HMI and Caltech together are the Parties).

AveXis, Inc. – First Amendment to License Agreement (February 28th, 2018)

This First Amendment to License Agreement (the "First Amendment") is made as of January 8, 2018 (the "First Amendment Effective Date") by and between REGENXBIO Inc. (formerly known as ReGenX Biosciences, LLC), a corporation organized under the laws of the State of Delaware, with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 ("Licensor"), and AveXis, Inc., a corporation organized under the laws of the State of Delaware, with offices at 2275 Half Day Road, Suite 200, Bannockburn, IL 60015 ("Licensee"). Licensor and Licensee are hereinafter referred to individually as a "Party" and collectively as the "Parties."

Homology Medicines, Inc. – Confidential Treatment Requested by Homology Medicines, Inc. FIRST AMENDMENT TO LICENSE AGREEMENT (January 30th, 2018)

This amendment to the License Agreement (the First License Amendment), effective on the date last signed below, (Amendment Effective Date) is by and between Homology Medicines, Inc., a Delaware corporation having a place of business at 45 Wiggins Avenue, Bedford, MA 01730 (HMI) and California Institute of Technology, a not-for-profit corporation duly organized and existing under the laws of the State of California with an address at 1200 East California Boulevard, MC 6-32, Pasadena, California 91125 (Caltech; HMI and Caltech together are the Parties).

Level Brands, Inc. – First Amendment to License Agreement (January 22nd, 2018)

THIS FIRST AMENDMENT ("First Amendment") is entered into as of January 19, 2018, by and between Isodiol International Inc., a Canadian corporation ("Licensee"), and Level Brands, Inc., a North Carolina corporation ("Licensor"), and amends, modifies, and supplements that certain License Agreement dated as of December 30, 2017 between the parties (the "Agreement").

GraniteShares Platinum Trust – Amendment to License Agreement (January 12th, 2018)

This Amendment (the "Amendment") is made as of November 3, 2017 by and between GRANITESHARES LLC ("Licensee") and THE BANK OF NEW YORK MELLON ("Licensor").

resTORbio, Inc. – [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED First Amendment to License Agreement (December 29th, 2017)

First Amendment to License Agreement (Amendment), made as of October 3, 2017 (Amendment Effective Date), to the License Agreement (Original Agreement), dated March 23, 2017 (the Original Agreement Effective Date), by and between Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (Novartis) and resTORbio, Inc., a Delaware corporation located at 501 Boylston Street, Suite 6102, Boston, Massachusetts 02116 (resTORbio). The Original Agreement, as amended by this Amendment, is referred to as the Agreement. Novartis and resTORbio are each referred to individually as a Party and together as the Parties.

resTORbio, Inc. – [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED First Amendment to License Agreement (December 22nd, 2017)

First Amendment to License Agreement (Amendment), made as of October 3, 2017 (Amendment Effective Date), to the License Agreement (Original Agreement), dated March 23, 2017 (the Original Agreement Effective Date), by and between Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (Novartis) and resTORbio, Inc., a Delaware corporation located at 501 Boylston Street, Suite 6102, Boston, Massachusetts 02116 (resTORbio). The Original Agreement, as amended by this Amendment, is referred to as the Agreement. Novartis and resTORbio are each referred to individually as a Party and together as the Parties.

Athersys – First Amendment to License Agreement (November 8th, 2017)

This First Amendment to the License Agreement (the First Amendment) is dated July 21, 2017 and amends the License Agreement dated January 8, 2016 (the Agreement) by and between ABT Holding Company (ATHX), a Delaware corporation having its principal place of business at 3201 Carnegie Avenue, Cleveland, OH 44115 and wholly-owned subsidiary of Athersys, Inc. (Athersys), and HEALIOS, K.K. (Healios), a Japanese company having its principal place of business at World Trade Center Bldg. 15F, 2-4-1 Hamamatsucho, Minato-ku, Tokyo 105-6115 Japan. All defined terms used but not defined in this First Amendment shall have the meanings ascribed to them in the Agreement.

Athersys – Second Amendment to License Agreement (November 8th, 2017)

This Second Amendment to the License Agreement (the Second Amendment) is dated September 19, 2017 and amends the License Agreement dated January 8, 2016 (the Agreement), as amended, by and between ABT Holding Company (ATHX), a Delaware corporation having its principal place of business at 3201 Carnegie Avenue, Cleveland, OH 44115 and wholly-owned subsidiary of Athersys, Inc. (Athersys), and HEALIOS, K.K. (Healios), a Japanese company having its principal place of business at World Trade Center Bldg. 15F, 2-4-1 Hamamatsucho, Minato-ku, Tokyo 105-6115 Japan. All defined terms used but not defined in this Second Amendment shall have the meanings ascribed to them in the Agreement.

Editas Medicine, Inc. – First Amendment to License Agreement (November 8th, 2017)

This First Amendment, dated September 1, 2017 (the "First Amendment"), is by and between Editas Medicine, Inc., a Delaware corporation ("Licensee") and Duke University, a nonprofit educational and research institution organized under the laws of North Carolina ("DUKE").

GraniteShares Platinum Trust – Amendment to License Agreement (November 3rd, 2017)

This Amendment (the "Amendment") is made as of November ___, 2017 by and between GRANITESHARES LLC ("Licensee") and THE BANK OF NEW YORK MELLON ("Licensor").

OptiNose, Inc. – Amendment to License Agreement (September 18th, 2017)

This AMENDMENT TO LICENSE AGREEMENT (this Amendment) is entered into on August 6, 2015 by and between OPTINOSE AS, a Norwegian corporation, company registration number 982483131 (OptiNose), with its principal place of business at Tore Hals Mejdells vei 7, 0751 Oslo, Norway, and its postal address at Pb 288 Roa, 0702 Oslo, Norway, and AVANIR PHARMACEUTICALS, INC., a Delaware corporation (Avanir), with offices at 30 Enterprise, Suite 400, Aliso Viejo, CA 92656, U.S.A. OptiNose and Avanir are sometimes referred to herein as a Party and collectively as the Parties.

Adma Biologics, Inc. – First Amendment to License Agreement (August 11th, 2017)

This First Amendment to the License Agreement ("Amendment #1") by and between Biotest Aktiengesellschaft, a corporation organized under the laws of Germany ("Biotest"), and ADMA Biologics, Inc., a Delaware corporation ("ADMA"), is effective as of June 6, 2017 ("Effective Date"). ADMA and Biotest are also referred to herein individually as a "Party" and collectively as the "Parties".

OptiNose, Inc. – Amendment to License Agreement (August 4th, 2017)

This AMENDMENT TO LICENSE AGREEMENT (this Amendment) is entered into on August 6, 2015 by and between OPTINOSE AS, a Norwegian corporation, company registration number 982483131 (OptiNose), with its principal place of business at Tore Hals Mejdells vei 7, 0751 Oslo, Norway, and its postal address at Pb 288 Roa, 0702 Oslo, Norway, and AVANIR PHARMACEUTICALS, INC., a Delaware corporation (Avanir), with offices at 30 Enterprise, Suite 400, Aliso Viejo, CA 92656, U.S.A. OptiNose and Avanir are sometimes referred to herein as a Party and collectively as the Parties.

First Amendment to License Agreement (May 18th, 2017)

THIS FIRST AMENDMENT TO LICENSE AGREEMENT (the Amendment) is entered into as of May 17, 2017 (the Amendment Effective Date), by and between Eli Lilly and Company, an Indiana corporation, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, (Lilly) and United Therapeutics Corporation, a Delaware corporation, having its principal place of business at 1040 Spring Street, Silver Spring, Maryland 20910 (United Therapeutics). Lilly and United Therapeutics are referred to individually as a Party and collectively as the Parties.

Amyris – First Amendment to License Agreement Regarding Diesel Fuel in the Eu (May 15th, 2017)

This First Amendment to License Agreement regarding Diesel Fuel in the EU (this "Amendment") is entered as of February 14, 2017 by and between Amyris, Inc., a corporation organizing and existing under the laws of the state of Delaware, with its place of business at 5885 Hollis Street, Suite 100, Emeryville, California 94608 ("Amyris") and Total Energies Nouvelles Activites USA SAS, a societe par actions simplifiee organized and existing under the laws of France, having its head-office at 24 Cours Michelet, 92800 Puteaux, France ("TOTAL"). AMYRIS and TOTAL are sometimes referred to herein individually as a "Party" and collectively as the "Parties".

Athenex, Inc. – Third Amendment to License Agreement (May 12th, 2017)

THIS THIRD AMENDMENT TO LICENSE AGREEMENT (this Third Amendment) is made and entered into as of March 3, 2015 (Effective Date), by and between KINEX PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware USA and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, United States (Kinex) and HANMI PHARMACEUTICAL LTD., a publicly traded company existing under the laws of South Korea and having its principal office at 14, Wiryeseong-daero,Songpa-gu, Seoul, 138-724 South Korea (Hanmi).

Athenex, Inc. – First Amendment to License Agreement (May 12th, 2017)

This FIRST AMENDMENT TO LICENSE AGREEMENT (this First Amendment) is made and entered into as of this 23rd day of December, 2016 (Effective Date) by and between Athenex, Inc., formerly known as Kinex Pharmaceuticals, LLC, a corporation organized and existing under the laws of the state of Delaware, USA, with a principal place of business at 1001 Main Street, Suite 600, Buffalo, New York 14203 (Athenex), and PharmaEssentia Corp., a publicly traded company organized and existing under the laws of Taiwan with a principal place of business at 13F., No. 3 YuanQu Street, Nankang District, Taipei 115, Taiwan (PharmaEssentia).

Athenex, Inc. – First Amendment to License Agreement (May 12th, 2017)

THIS FIRST AMENDMENT TO LICENSE AGREEMENT (this First Amendment) is made and entered into as of November 9, 2012 (Effective Date), by and between KINEX PHARMACEUTICALS, LLC, a limited liability company organized and existing under the laws of the State of New York and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, United States (Kinex) and HANMI PHARMACEUTICAL CO., LTD., a publicly traded company existing under the laws of Republic of Korea and having its principal office at 14, Wiryeseong-daero, Songpa-gu, Seoul, 138-724, Republic of Korea (Hanmi).

Athenex, Inc. – First Amendment to License Agreement (May 12th, 2017)

This FIRST AMENDMENT TO LICENSE AGREEMENT (this First Amendment) is made and entered into as of this 23rd day of December, 2016 (Effective Date) by and between Athenex, Inc., formerly known as Kinex Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware, USA, with a principal place of business at 1001 Main Street, Suite 600, Buffalo, New York 14203 (Athenex), and PharmaEssentia Corp., a publicly traded company organized and existing under the laws of Taiwan with a principal place of business at 13F., No. 3 YuanQu Street, Nangang District, Taipei 115, Taiwan (PharmaEssentia).

Athenex, Inc. – Second Amendment to License Agreement (May 12th, 2017)

THIS SECOND AMENDMENT TO LICENSE AGREEMENT (this Second Amendment) is made and entered into as of October 21, 2013 (Effective Date), by and between KINEX PHARMACEUTICALS, INC. (formerly Kinex Pharmaceuticals, LLC), a corporation organized and existing under the laws of the State of Delaware and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, United States (Kinex) and HANMI PHARMACEUTICAL LTD., a publicly traded company existing under the laws of South Korea and having its principal office at 14, Wiryeseong-daero, Songpa-gu, Seoul, 138-724 South Korea (Hanmi).

Athenex, Inc. – Fourth Amendment to License Agreement (May 12th, 2017)

THIS FOURTH AMENDMENT TO LICENSE AGREEMENT (this Fourth Amendment) is made and entered as of March 7, 2017 (Effective Date), by and between ATHENEX INC., (formerly known as Kinex Pharmaceuticals INC. and prior, Kinex Pharmaceuticals, LLC.), a corporation organized and existing under the laws of the State of Delaware, and having its principal office in Suite 600, Conventus Building, 1001 Main Street, Buffalo, New York 14203, United States (Athenex) and HANMI PHARMACEUTICAL CO., LTD., a publicly traded company existing under the laws of South Korea and having its principal office at 14, Wiryeseong-daero, Songpa-gu, Seoul, 05545, South Korea (Hanmi).

Checkpoint Therapeutics, Inc. – SECOND AMENDMENT TO LICENSE AGREEMENT (Amendment # 2) (May 10th, 2017)

THIS SECOND AMENDMENT TO LICENSE AGREEMENT (this "Amendment") is made as of March 31, 2017 (the "Effective Date") between Jubilant Biosys Limited, a company organized under the laws of India, having its principal place of business at No. 96, Industrial Suburb, 2nd Stage, Yeshwanthpur, Bangalore - 560022, India ("Licensor"), and Checkpoint Therapeutics, Inc, a Delaware corporation with its place of business at 2 Gansevoort Street, 9th Floor, New York, New York 10014 ("Checkpoint").

Airxpanders Inc – First Amendment to License Agreement (May 1st, 2017)

This FIRST AMENDMENT (Amendment) to license agreement is effective as of March 9, 2009 and is made by and between Shalon Ventures, Inc., a California corporation (SV) and AirXpanders, Inc., a Delaware corporation (Licensee).

Athenex, Inc. – Third Amendment to License Agreement (May 1st, 2017)

THIS THIRD AMENDMENT TO LICENSE AGREEMENT (this Third Amendment) is made and entered into as of March 3, 2015 (Effective Date), by and between KINEX PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware USA and having its principal office at 701 Ellicott Street, Buffalo, New York 14203, United States (Kinex) and HANMI PHARMACEUTICAL LTD., a publicly traded company existing under the laws of South Korea and having its principal office at 14, Wiryeseong-daero,Songpa-gu, Seoul, 138-724 South Korea (Hanmi).

Kitov Pharmaceuticals Holdings Ltd. – The Symbol "[****]" Denotes Places Where Portions of This Document Have Been Omiitted Pursuant to a Request for Confidential Treatment. Such Material Has Been Filed Separately With the Securities and Exchange Commission First Amendment to License Agreement (May 1st, 2017)

This First Amendment to License Agreement ("First Amendment") is effective as of 8 April, 2014 (the "Effective Date"), by and between, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J Safra Campus, Givat Ram, Jerusalem 91390 Israel, ("Yissum") of the one part; and

Airxpanders Inc – Second Amendment to License Agreement (May 1st, 2017)

This SECOND AMENDMENT (Amendment) to license agreement is effective as of January 9, 2012 (the Amendment Effective Date) and is made by and between Shalon Ventures, Inc., a California corporation (SV) and AirXpanders, Inc., a Delaware corporation (Licensee).

Athenex, Inc. – Fourth Amendment to License Agreement (May 1st, 2017)

THIS FOURTH AMENDMENT TO LICENSE AGREEMENT (this Fourth Amendment) is made and entered as of March 7, 2017 (Effective Date), by and between ATHENEX INC., (formerly known as Kinex Pharmaceuticals INC. and prior, Kinex Pharmaceuticals, LLC.), a corporation organized and existing under the laws of the State of Delaware, and having its principal office in Suite 600, Conventus Building, 1001 Main Street, Buffalo, New York 14203, United States (Athenex) and HANMI PHARMACEUTICAL CO., LTD., a publicly traded company existing under the laws of South Korea and having its principal office at 14, Wiryeseong-daero, Songpa-gu, Seoul, 05545, South Korea (Hanmi).